Skip to main content
Top
Published in: Archives of Virology 2/2015

01-02-2015 | Original Article

The N-linked glycosylation site at position 158 on the head of hemagglutinin and the virulence of H5N1 avian influenza virus in mice

Authors: Ornpreya Suptawiwat, Chompunuch Boonarkart, Warunya Chakritbudsabong, Mongkol Uiprasertkul, Pilaipan Puthavathana, Witthawat Wiriyarat, Prasert Auewarakul

Published in: Archives of Virology | Issue 2/2015

Login to get access

Abstract

N-linked glycosylation of the influenza virus hemagglutinin (HA) protein plays crucial roles in HA structure and function, evasion of neutralizing antibodies, and susceptibility to innate soluble antiviral factors. The N-linked glycosylation site at position 158 of highly pathogenic H5N1 virus was previously shown to affect viral receptor-binding preference. H5N1 viruses show heterogeneity with respect to the presence of this glycosylation site. Clade 1 viruses that caused outbreaks in Southeast Asia in 2004 contained this glycosylation site, while the site is absent in the more recent clade 2 viruses. Here, we show that elimination of this glycosylation site increases viral virulence in mice. The mutant lacking the glycosylation site at position 158 showed unaltered growth kinetics in vitro and a comparable level of sensitivity to a major antiviral protein found in respiratory secretions, surfactant protein D (SP-D).
Literature
1.
go back to reference Klenk HD, Wagner R, Heuer D, Wolff T (2002) Importance of hemagglutinin glycosylation for the biological functions of influenza virus. Virus Res 82(1–2):73–75PubMed Klenk HD, Wagner R, Heuer D, Wolff T (2002) Importance of hemagglutinin glycosylation for the biological functions of influenza virus. Virus Res 82(1–2):73–75PubMed
2.
go back to reference Schulze IT (1997) Effects of glycosylation on the properties and functions of influenza virus hemagglutinin. J Infect Dis 176(Suppl 1):S24–S28PubMedCrossRef Schulze IT (1997) Effects of glycosylation on the properties and functions of influenza virus hemagglutinin. J Infect Dis 176(Suppl 1):S24–S28PubMedCrossRef
3.
go back to reference Tate MD, Job ER, Deng YM, Gunalan V, Maurer-Stroh S, Reading PC (2014) Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses 6(3):1294–1316. doi:10.3390/v6031294 PubMedCentralPubMedCrossRef Tate MD, Job ER, Deng YM, Gunalan V, Maurer-Stroh S, Reading PC (2014) Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses 6(3):1294–1316. doi:10.​3390/​v6031294 PubMedCentralPubMedCrossRef
5.
go back to reference Hartshorn KL, Crouch EC, White MR, Eggleton P, Tauber AI, Chang D, Sastry K (1994) Evidence for a protective role of pulmonary surfactant protein D (SP-D) against influenza A viruses. J Clin Invest 94:311–319PubMedCentralPubMedCrossRef Hartshorn KL, Crouch EC, White MR, Eggleton P, Tauber AI, Chang D, Sastry K (1994) Evidence for a protective role of pulmonary surfactant protein D (SP-D) against influenza A viruses. J Clin Invest 94:311–319PubMedCentralPubMedCrossRef
10.
11.
go back to reference Matsuoka Y, Swayne DE, Thomas C, Rameix-Welti MA, Naffakh N, Warnes C, Altholtz M, Donis R, Subbarao K (2009) Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice. J Virol 83(9):4704–4708. doi:10.1128/JVI.01987-08 PubMedCentralPubMedCrossRef Matsuoka Y, Swayne DE, Thomas C, Rameix-Welti MA, Naffakh N, Warnes C, Altholtz M, Donis R, Subbarao K (2009) Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice. J Virol 83(9):4704–4708. doi:10.​1128/​JVI.​01987-08 PubMedCentralPubMedCrossRef
12.
go back to reference Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR (2001) Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 146(12):2275–2289PubMedCrossRef Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR (2001) Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 146(12):2275–2289PubMedCrossRef
15.
go back to reference Ngaosuwankul N, Noisumdaeng P, Komolsiri P, Pooruk P, Chokephaibulkit K, Chotpitayasunondh T, Sangsajja C, Chuchottaworn C, Farrar J, Puthavathana P (2010) Influenza A viral loads in respiratory samples collected from patients infected with pandemic H1N1, seasonal H1N1 and H3N2 viruses. Virol J 7:75PubMedCentralPubMedCrossRef Ngaosuwankul N, Noisumdaeng P, Komolsiri P, Pooruk P, Chokephaibulkit K, Chotpitayasunondh T, Sangsajja C, Chuchottaworn C, Farrar J, Puthavathana P (2010) Influenza A viral loads in respiratory samples collected from patients infected with pandemic H1N1, seasonal H1N1 and H3N2 viruses. Virol J 7:75PubMedCentralPubMedCrossRef
16.
go back to reference Reading PC, Morey LS, Crouch EC, Anders EM (1997) Collectin-mediated antiviral host defense of the lung: evidence from influenza virus infection of mice. J Virol 71(11):8204–8212PubMedCentralPubMed Reading PC, Morey LS, Crouch EC, Anders EM (1997) Collectin-mediated antiviral host defense of the lung: evidence from influenza virus infection of mice. J Virol 71(11):8204–8212PubMedCentralPubMed
18.
20.
go back to reference Hillaire ML, Haagsman HP, Osterhaus AD, Rimmelzwaan GF, van Eijk M (2013) Pulmonary surfactant protein D in first-line innate defence against influenza A virus infections. J Innate Immun 5(3):197–208. doi:10.1159/000346374 PubMedCrossRef Hillaire ML, Haagsman HP, Osterhaus AD, Rimmelzwaan GF, van Eijk M (2013) Pulmonary surfactant protein D in first-line innate defence against influenza A virus infections. J Innate Immun 5(3):197–208. doi:10.​1159/​000346374 PubMedCrossRef
21.
go back to reference LeVine AM, Whitsett JA, Hartshorn KL, Crouch EC, Korfhagen TR (2001) Surfactant protein D enhances clearance of influenza A virus from the lung in vivo. J Immunol 167(10):5868–5873PubMedCrossRef LeVine AM, Whitsett JA, Hartshorn KL, Crouch EC, Korfhagen TR (2001) Surfactant protein D enhances clearance of influenza A virus from the lung in vivo. J Immunol 167(10):5868–5873PubMedCrossRef
22.
go back to reference Stuart LM, Henson PM, Vandivier RW (2006) Collectins: opsonins for apoptotic cells and regulators of inflammation. Curr Dir Autoimmun 9:143–161. doi:10.1159/000090778 PubMed Stuart LM, Henson PM, Vandivier RW (2006) Collectins: opsonins for apoptotic cells and regulators of inflammation. Curr Dir Autoimmun 9:143–161. doi:10.​1159/​000090778 PubMed
23.
go back to reference Kongchanagul A, Suptawiwat O, Boonarkart C, Kitphati R, Puthavathana P, Uiprasertkul M, Auewarakul P (2011) Decreased expression of surfactant protein D mRNA in human lungs in fatal cases of H5N1 avian influenza. J Med Virol 83(8):1410–1417. doi:10.1002/jm PubMedCrossRef Kongchanagul A, Suptawiwat O, Boonarkart C, Kitphati R, Puthavathana P, Uiprasertkul M, Auewarakul P (2011) Decreased expression of surfactant protein D mRNA in human lungs in fatal cases of H5N1 avian influenza. J Med Virol 83(8):1410–1417. doi:10.​1002/​jm PubMedCrossRef
Metadata
Title
The N-linked glycosylation site at position 158 on the head of hemagglutinin and the virulence of H5N1 avian influenza virus in mice
Authors
Ornpreya Suptawiwat
Chompunuch Boonarkart
Warunya Chakritbudsabong
Mongkol Uiprasertkul
Pilaipan Puthavathana
Witthawat Wiriyarat
Prasert Auewarakul
Publication date
01-02-2015
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 2/2015
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-014-2306-x

Other articles of this Issue 2/2015

Archives of Virology 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine